HALLE/SAALE, Germany, October 21, 2013 – Probiodrug AG (Probiodrug) today announced that Dr Glund Konrad, the Company’s chief executive officer will be providing an update of corporate and clinical accomplishments at the Sofinnova Japan Biopharma Partnering Conference, on Tuesday, October 22, 2013, at 10:35 a.m. JST. The conference is taking place at the Conrad Hotel in Tokyo, Japan.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as Edmond de Rothschild Investment Partners, BB Biotech, IBG, HBM, TVM Capital, Life Sciences Partners, Biogen
Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof Dr Hans-Ulrich Demuth and Dr Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900